En aquest article volem revisar la diversitat dels mecanismes moleculars suposadament res-ponsables del creixement independent d’andrògens del càncer de pròstata. Es demostra que alguns càncers de pròstata que escapen de la teràpia endocrinològica estan compostos per cèl-lules sensibles als andrògens. Ens centrarem en els resultats del nostre laboratori i en els d’altres grups de recerca que sugge-reixen el mateix concepte nou: el comportament del càncer de pròstata refractari als andrògens està associat a una resposta invertida de les cèll. ules als andrògens. Hem observat un alentiment paradoxal en el creixement de diverses línies cell. ulars induït pels andrògens. Aquestes línies cell. ulars provenen de les cèll. ules LNCaP, ja sigui per...
Androgen-deprivation therapy (ADT) has been for many years the cornerstone of metastatic prostate ca...
Copyright © 2013 Jesal C. Patel et al. This is an open access article distributed under the Creative...
In recent years, many therapeutic advances have been made in the management of castration-resistant ...
En aquest article volem revisar la diversitat dels mecanismes moleculars suposadament responsables d...
Apart from skin cancer, prostate cancer is the most common form of cancer in men and the second lead...
Prostate cancer (CaP) is the leading cause of cancer in men affecting 24,700 Canadians each year and...
One in 10 men in the developed world will present with prostate cancer (CaP), and in an ageing popul...
Secondary hormonal therapy is a treatment option in patients with castration-resistant prostate canc...
Des mutations non-sens conduisant à la perte partielle ou totale de la région carboxy-terminale du r...
Le cancer de la prostate constitue un problème de santé publique important, il se situe en France au...
CONTEXT: Androgen deprivation therapy (ADT) is the backbone of treatment for advanced prostate cance...
Parallèlement au rôle central du récepteur aux androgènes, l’environnement tumoral immédiat exerce a...
Abstract Prostate cancer is the most frequently diagnosed non-cutaneous tumor of men in Western coun...
Abstract: Prostate cancer is the most commonly diagnosed nonskin cancer and the second leading cause...
En France, le cancer de la prostate est le premier cancer par son incidence ainsi que la troisième c...
Androgen-deprivation therapy (ADT) has been for many years the cornerstone of metastatic prostate ca...
Copyright © 2013 Jesal C. Patel et al. This is an open access article distributed under the Creative...
In recent years, many therapeutic advances have been made in the management of castration-resistant ...
En aquest article volem revisar la diversitat dels mecanismes moleculars suposadament responsables d...
Apart from skin cancer, prostate cancer is the most common form of cancer in men and the second lead...
Prostate cancer (CaP) is the leading cause of cancer in men affecting 24,700 Canadians each year and...
One in 10 men in the developed world will present with prostate cancer (CaP), and in an ageing popul...
Secondary hormonal therapy is a treatment option in patients with castration-resistant prostate canc...
Des mutations non-sens conduisant à la perte partielle ou totale de la région carboxy-terminale du r...
Le cancer de la prostate constitue un problème de santé publique important, il se situe en France au...
CONTEXT: Androgen deprivation therapy (ADT) is the backbone of treatment for advanced prostate cance...
Parallèlement au rôle central du récepteur aux androgènes, l’environnement tumoral immédiat exerce a...
Abstract Prostate cancer is the most frequently diagnosed non-cutaneous tumor of men in Western coun...
Abstract: Prostate cancer is the most commonly diagnosed nonskin cancer and the second leading cause...
En France, le cancer de la prostate est le premier cancer par son incidence ainsi que la troisième c...
Androgen-deprivation therapy (ADT) has been for many years the cornerstone of metastatic prostate ca...
Copyright © 2013 Jesal C. Patel et al. This is an open access article distributed under the Creative...
In recent years, many therapeutic advances have been made in the management of castration-resistant ...